Organogenesis Holdings Inc. looks undervalued at distressed multiples; new DFU RCT data supports coverage despite 2026 CMS ...
Shares of Organogenesis Holdings were higher after the company said its product for non-healing diabetic foot ulcers met its primary endpoint in a recent trial. The stock rose 30%, to $2.91, in ...
13hon MSN
Organogenesis stock rockets after diabetic foot ulcer trial posts statistically significant win
Organogenesis Holdings Inc. ORGO shares are up during Tuesday’s premarket session following the company’s announcement of achieving the primary endpoint in a randomized controlled trial evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results